Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial

@inproceedings{Manders2015CosteffectivenessOA,
  title={Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial},
  author={Sofie H M Manders and Wietske Kievit and Eddy M M Adang and Herman L. M. Brus and Hein J. Bernelot Moens and Andre Hartkamp and Lidy Hendriks and Elisabeth Cath{\'e}rine Brouwer and Henk Visser and Harald E. Vonkeman and Jos Hendrikx and Tim Jansen and Ren{\'e} Westhovens and Mart Afj van de Laar and Piet L. C. M. van Riel},
  booktitle={Arthritis research & therapy},
  year={2015}
}
INTRODUCTION For patients with rheumatoid arthritis (RA) whose treatment with a tumour necrosis factor inhibitor (TNFi) is failing, several biological treatment options are available. Often, another TNFi or a biological with another mode of action is prescribed. The objective of this study was to compare the effectiveness and cost-effectiveness of three… CONTINUE READING